Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data for its COVID-19 treatment, EDP-235, presented at IDWeek 2022 in Washington, DC. The data indicates EDP-235 effectively penetrates target tissues, including macrophages and monocytes, potentially mitigating cytokine storms in high-risk patients. Enanta plans to initiate a Phase 2 study of EDP-235 this quarter. The drug showed favorable safety and pharmacokinetics in earlier studies, positioning it as a potential best-in-class antiviral.
Enanta Pharmaceuticals (NASDAQ:ENTA) has initiated its Phase 1 clinical trial for EDP-323, an oral L-protein inhibitor targeting respiratory syncytial virus (RSV). This milestone follows promising preclinical data indicating EDP-323's effectiveness across RSV genotypes. The trial will enroll around 80 healthy participants to assess safety and pharmacokinetics, including randomized doses of EDP-323 and a placebo. RSV poses significant health risks, especially in young children and older adults. With EDP-323, Enanta aims to enhance its RSV treatment portfolio while potential benefits for patients are anticipated.
Enanta Pharmaceuticals (NASDAQ:ENTA) has initiated a Phase 2b study to assess the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults at high risk of complications from acute respiratory syncytial virus (RSV) infection. The study will involve approximately 180 participants treated with EDP-938 or placebo over 5 days, with evaluations made for 28 days post-treatment. Previous studies indicated EDP-938's ability to significantly reduce RSV RNA levels and its favorable safety profile, supporting its potential for optimal clinical benefit.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced promising preclinical data on EDP-323, a novel non-nucleoside RSV L-inhibitor, and advancements in virology methods for RSV and hMPV research. Presented at the 12th International RSV Symposium, EDP-323 showed potent inhibition of RSV replication in various models, including a mouse infection model that demonstrated improved lung histopathology. The company's research is supported by royalties from its collaboration with AbbVie on hepatitis C treatments, aiding the advance of its pipeline for respiratory viral infections.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced new preclinical data for its respiratory syncytial virus (RSV) program, set to be presented at the 12th International RSV Symposium from September 29 to October 2, 2022, in Belfast, UK. Highlights include an oral presentation titled “EDP-323, a Novel L-Protein Inhibitor, for the Treatment of RSV” scheduled for October 1, and multiple poster presentations on September 30. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, funded by royalties from hepatitis C virus products.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced new preclinical data for EDP-235, its oral coronavirus protease inhibitor aimed at treating COVID-19, to be presented at IDWeek 2022 from October 19-23, 2022, in Washington, DC. An oral presentation is scheduled for October 21, 2022, at 12:15 PM ET, discussing EDP-235's potential to mitigate cytokine storms in high-risk COVID-19 patients. Enanta continues its focus on small molecule drugs for viral infections and liver diseases, supported by royalties from its collaboration with AbbVie on hepatitis C virus products.
Enanta Pharmaceuticals (NASDAQ: ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, will feature CEO Jay R. Luly, Ph.D., at two investor conferences in September 2022. He will present at the Wells Fargo Healthcare Conference on September 8 at 3:10 p.m. ET, followed by a fireside chat at the Baird Global Healthcare Conference on September 13 at 9:40 a.m. ET. Live webcasts will be available on Enanta’s website, with replays accessible for 30 days after the events.
Enanta Pharmaceuticals reported fiscal Q3 2022 revenue of $19.5 million, primarily from royalties on AbbVie's MAVYRET®, a decline from $21.6 million in Q3 2021. R&D expenses decreased to $39.1 million from $47.0 million, while G&A expenses rose to $12.9 million from $8.5 million. The net loss was $31.7 million ($1.53 per share), compared to $24.0 million ($1.19 per share) in the previous year. Enanta plans to initiate Phase 2 studies for its COVID-19 treatment EDP-235 and RSV treatment EDP-938 in Q4 2022.
Enanta Pharmaceuticals, a clinical-stage biotechnology company, appointed Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer on August 8, 2022. Dr. Rottinghaus brings over 20 years of drug development experience, notably leading clinical programs at Alexion and Pfizer. His expertise will support Enanta's ongoing clinical programs, including a Phase 2 study on COVID-19 and advancements in respiratory syncytial virus (RSV). This appointment aims to further Enanta's goal of becoming a leader in antiviral treatments.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is set to announce its financial results for Q3 2022, concluded on June 30, 2022, on August 8, 2022, post-market. A conference call will be held at 4:30 p.m. ET the same day to discuss the results and updates on the company’s R&D pipeline. Enanta focuses on drug discovery for viral infections and liver diseases, including respiratory syncytial virus (RSV) and hepatitis B virus (HBV), while funding is supported by royalties from its collaboration with AbbVie on hepatitis C virus (HCV) treatments.